RU2008103608A - Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела - Google Patents
Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела Download PDFInfo
- Publication number
- RU2008103608A RU2008103608A RU2008103608/15A RU2008103608A RU2008103608A RU 2008103608 A RU2008103608 A RU 2008103608A RU 2008103608/15 A RU2008103608/15 A RU 2008103608/15A RU 2008103608 A RU2008103608 A RU 2008103608A RU 2008103608 A RU2008103608 A RU 2008103608A
- Authority
- RU
- Russia
- Prior art keywords
- therapeutic antibody
- target antigen
- sample
- antibody
- complex
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract 26
- 239000000427 antigen Substances 0.000 title claims abstract 17
- 102000036639 antigens Human genes 0.000 title claims abstract 17
- 108091007433 antigens Proteins 0.000 title claims abstract 17
- 238000000034 method Methods 0.000 claims abstract 21
- 238000003018 immunoassay Methods 0.000 claims abstract 6
- 230000015572 biosynthetic process Effects 0.000 claims abstract 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims abstract 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims abstract 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract 2
- 229940120638 avastin Drugs 0.000 claims abstract 2
- 229940022353 herceptin Drugs 0.000 claims abstract 2
- 229960004641 rituximab Drugs 0.000 claims abstract 2
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05014618.2 | 2005-07-06 | ||
| EP05014618 | 2005-07-06 | ||
| EP06004447.6 | 2006-03-06 | ||
| EP06004447 | 2006-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008103608A true RU2008103608A (ru) | 2009-08-20 |
Family
ID=36922121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008103608/15A RU2008103608A (ru) | 2005-07-06 | 2006-07-05 | Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20070009976A1 (enExample) |
| EP (2) | EP1902315A1 (enExample) |
| JP (1) | JP2008545145A (enExample) |
| KR (1) | KR20080016939A (enExample) |
| AR (1) | AR053948A1 (enExample) |
| AU (1) | AU2006265275A1 (enExample) |
| BR (1) | BRPI0612591A2 (enExample) |
| CA (1) | CA2613187A1 (enExample) |
| CR (1) | CR9635A (enExample) |
| EC (1) | ECSP088081A (enExample) |
| IL (1) | IL188317A0 (enExample) |
| MA (1) | MA29730B1 (enExample) |
| MX (1) | MX2008000277A (enExample) |
| MY (1) | MY157955A (enExample) |
| NO (1) | NO20076662L (enExample) |
| NZ (1) | NZ564471A (enExample) |
| RU (1) | RU2008103608A (enExample) |
| TW (1) | TWI312864B (enExample) |
| WO (1) | WO2007003420A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001089566A1 (en) | 2000-05-19 | 2001-11-29 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| UA90480C2 (uk) * | 2004-07-22 | 2010-05-11 | Джэнэнтэк, Инк. | Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2 |
| WO2006039486A2 (en) | 2004-10-01 | 2006-04-13 | The Board Of Trustees Of The Leland Stanford Junior University | Imaging arrangements and methods therefor |
| WO2007092545A2 (en) | 2006-02-07 | 2007-08-16 | The Board Of Trustees Of The Leland Stanford Junior University | Variable imaging arrangements and methods therefor |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| RS53128B (sr) | 2005-02-23 | 2014-06-30 | Genentech Inc. | Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US8358354B2 (en) | 2009-01-26 | 2013-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Correction of optical abberations |
| MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| HUE044352T2 (hu) | 2011-10-14 | 2019-10-28 | Hoffmann La Roche | Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére |
| KR101327542B1 (ko) * | 2012-03-15 | 2013-11-08 | 광주과학기술원 | 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법 |
| AU2012232949B2 (en) * | 2012-09-28 | 2014-07-03 | Willowtree Holdings Pty Ltd | Temporary bulkhead |
| MY173295A (en) | 2013-04-16 | 2020-01-14 | Genentech Inc | Pertuzumab variants and evaluation thereof |
| BR112016024789A2 (pt) | 2014-04-25 | 2017-10-24 | Genentech Inc | métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe |
| JP6822980B2 (ja) | 2015-05-30 | 2021-01-27 | ジェネンテック， インコーポレイテッド | Ｈｅｒ２陽性転移性乳癌の治療方法 |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| JP6914336B2 (ja) | 2016-12-28 | 2021-08-04 | ジェネンテック， インコーポレイテッド | 進行したｈｅｒ２発現がんの治療 |
| DK3570884T3 (da) | 2017-01-17 | 2020-11-30 | Genentech Inc | Subkutane HER2-antistofformuleringer |
| HUE064898T2 (hu) | 2017-03-02 | 2024-04-28 | Genentech Inc | HER2-pozitív emlõrák adjuváns kezelése |
| WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
| JP2023532122A (ja) | 2020-06-29 | 2023-07-26 | ジェネンテック， インコーポレイテッド | ペルツズマブにトラスツズマブを加えた固定用量配合剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2095818B (en) | 1981-03-27 | 1985-10-02 | Exxon Research Engineering Co | Staged adsorption/resorption heat pump |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0590058B1 (en) * | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
| CN101412758A (zh) | 1996-10-18 | 2009-04-22 | 基因技术股份有限公司 | 抗ErbB2抗体 |
| DE60233744D1 (de) * | 2001-09-20 | 2009-10-29 | Univ Texas | Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests |
| HUP0600340A3 (en) * | 2002-07-15 | 2011-06-28 | Genentech Inc | Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies |
-
2006
- 2006-06-29 US US11/477,772 patent/US20070009976A1/en not_active Abandoned
- 2006-06-29 MY MYPI20063118A patent/MY157955A/en unknown
- 2006-07-04 TW TW095124248A patent/TWI312864B/zh active
- 2006-07-04 AR ARP060102872A patent/AR053948A1/es not_active Application Discontinuation
- 2006-07-05 MX MX2008000277A patent/MX2008000277A/es not_active Application Discontinuation
- 2006-07-05 KR KR1020087000259A patent/KR20080016939A/ko not_active Ceased
- 2006-07-05 BR BRPI0612591-3A patent/BRPI0612591A2/pt not_active IP Right Cessation
- 2006-07-05 EP EP06754671A patent/EP1902315A1/en not_active Withdrawn
- 2006-07-05 AU AU2006265275A patent/AU2006265275A1/en not_active Abandoned
- 2006-07-05 NZ NZ564471A patent/NZ564471A/en unknown
- 2006-07-05 CA CA002613187A patent/CA2613187A1/en not_active Abandoned
- 2006-07-05 RU RU2008103608/15A patent/RU2008103608A/ru unknown
- 2006-07-05 EP EP10157725A patent/EP2194380A3/en not_active Withdrawn
- 2006-07-05 WO PCT/EP2006/006524 patent/WO2007003420A1/en not_active Ceased
- 2006-07-05 JP JP2008519853A patent/JP2008545145A/ja active Pending
-
2007
- 2007-12-20 IL IL188317A patent/IL188317A0/en unknown
- 2007-12-21 CR CR9635A patent/CR9635A/es not_active Application Discontinuation
- 2007-12-28 NO NO20076662A patent/NO20076662L/no not_active Application Discontinuation
-
2008
- 2008-01-04 EC EC2008008081A patent/ECSP088081A/es unknown
- 2008-02-01 MA MA30617A patent/MA29730B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR053948A1 (es) | 2007-05-23 |
| US20070009976A1 (en) | 2007-01-11 |
| EP2194380A2 (en) | 2010-06-09 |
| TWI312864B (en) | 2009-08-01 |
| BRPI0612591A2 (pt) | 2010-11-23 |
| MY157955A (en) | 2016-08-30 |
| EP2194380A3 (en) | 2010-07-14 |
| JP2008545145A (ja) | 2008-12-11 |
| ECSP088081A (es) | 2008-02-20 |
| KR20080016939A (ko) | 2008-02-22 |
| CR9635A (es) | 2008-02-20 |
| WO2007003420A1 (en) | 2007-01-11 |
| NO20076662L (no) | 2008-04-03 |
| TW200741203A (en) | 2007-11-01 |
| IL188317A0 (en) | 2008-04-13 |
| EP1902315A1 (en) | 2008-03-26 |
| AU2006265275A1 (en) | 2007-01-11 |
| CA2613187A1 (en) | 2007-01-11 |
| MA29730B1 (fr) | 2008-09-01 |
| NZ564471A (en) | 2010-04-30 |
| MX2008000277A (es) | 2008-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312534A (pt) | método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura | |
| CN110383068A (zh) | 评估患者样品中uch-l1状态的改进方法 | |
| JP2008545145A5 (enExample) | ||
| CN110546513A (zh) | 使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法 | |
| DK1668368T3 (da) | Detektion af histon-modifikation i cellefrie nukleosomer | |
| JP2020517306A5 (enExample) | ||
| WO2018175942A1 (en) | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 | |
| WO2010038974A3 (ko) | 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트 | |
| FR2933773B1 (fr) | Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal | |
| EP2194380A3 (en) | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody | |
| RU2014103054A (ru) | Применение антитела i-3859 для выявления и диагностики рака | |
| Lei et al. | Application of an immunomagnetic bead ELISA based on IgY for detection of circulating antigen in urine of mice infected with Schistosoma japonicum | |
| JP4608432B2 (ja) | 腫瘍マーカーとしてのｎ▲１▼，ｎ▲１２▼−ジアセチルスペルミン | |
| WO2017125892A3 (es) | Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv | |
| US20150198598A1 (en) | Kit for diagnosing malignant melanoma | |
| CN109313201B (zh) | 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体 | |
| EP3602069A1 (en) | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 | |
| JP2025503439A (ja) | 血液試料におけるｕｃｈ－ｌ１、ｇｆａｐ及び他のバイオマーカーを決定するためのシステム及び方法 | |
| ATE532796T1 (de) | Immunassays zur spezifischen bestimmung von scca- isoformen | |
| ATE493662T1 (de) | Diagnostischer test für menschliches matrix gla- protein und seine verwendung als biomarker | |
| EP4396587A1 (en) | Methods and systems of diagnosing brain injury | |
| RU2012126312A (ru) | Маркерный белок для диабета типа 2 | |
| WO2024040238A3 (en) | Method of diagnosing and treating prostate cancer using zinc finger protein-like 1 antibodies | |
| EA202090834A1 (ru) | Набор реагентов для выявления маркера эпителиальных карцином | |
| TH86235A (th) | การตรวจหาแอนติเจนเป้าหมายโดยไม่คำนึงว่ามีแอนติบอดีรักษาโรคที่สมนัยกันหรือไม่มีก็ได้ |